Melphalan 200 mg/m2 in patients with renal impairment is associated with increased short-term toxicity but improved response and longer treatment-free survival.
about
Melphalan hydrochloride for the treatment of multiple myeloma.Autologous hematopoietic cell transplantation for multiple myeloma patients with renal insufficiency: a center for international blood and marrow transplant research analysis.Melphalan 140mg/m2 or 200mg/m2 for autologous transplantation in myeloma: results from the Collaboration to Collect Autologous Transplant Outcomes in Lymphoma and Myeloma (CALM) study. A report by the EBMT Chronic Malignancies Working Party.
P2860
Melphalan 200 mg/m2 in patients with renal impairment is associated with increased short-term toxicity but improved response and longer treatment-free survival.
description
2016 nî lūn-bûn
@nan
2016年の論文
@ja
2016年学术文章
@wuu
2016年学术文章
@zh-cn
2016年学术文章
@zh-hans
2016年学术文章
@zh-my
2016年学术文章
@zh-sg
2016年學術文章
@yue
2016年學術文章
@zh
2016年學術文章
@zh-hant
name
Melphalan 200 mg/m2 in patient ...... onger treatment-free survival.
@en
Melphalan 200 mg/m2 in patient ...... onger treatment-free survival.
@nl
type
label
Melphalan 200 mg/m2 in patient ...... onger treatment-free survival.
@en
Melphalan 200 mg/m2 in patient ...... onger treatment-free survival.
@nl
prefLabel
Melphalan 200 mg/m2 in patient ...... onger treatment-free survival.
@en
Melphalan 200 mg/m2 in patient ...... onger treatment-free survival.
@nl
P2093
P2860
P356
P1476
Melphalan 200 mg/m2 in patient ...... onger treatment-free survival.
@en
P2093
P2860
P2888
P304
P356
10.1038/BMT.2016.136
P407
P577
2016-05-16T00:00:00Z
P6179
1047860838